Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.
- DOI
- 10.1038/s41391-026-01145-0
- Published
- 2026 Aug 5
- Container
- Prostate cancer and prostatic diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41391-026-01145-0,
title = {Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.},
author = {McKenzie J and Howard L and Park JJ and Ashraf B and Seibert T and White K and Ramalingam S and Shevach JW and Harrison MR and Hoimes C and Labriola M and Infield J and Cockrell D and McManus HD and George DJ and Armstrong AJ},
year = {2026},
journal = {Prostate cancer and prostatic diseases},
doi = {10.1038/s41391-026-01145-0},
url = {https://doi.org/10.1038/s41391-026-01145-0}
}RIS
TY - JOUR TI - Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer. AU - McKenzie J AU - Howard L AU - Park JJ AU - Ashraf B AU - Seibert T AU - White K AU - Ramalingam S AU - Shevach JW AU - Harrison MR AU - Hoimes C AU - Labriola M AU - Infield J AU - Cockrell D AU - McManus HD AU - George DJ AU - Armstrong AJ PY - 2026 JO - Prostate cancer and prostatic diseases DO - 10.1038/s41391-026-01145-0 UR - https://doi.org/10.1038/s41391-026-01145-0 ER -
APA
J, M., L, H., JJ, P., B, A., T, S., K, W., S, R., JW, S., MR, H., C, H., M, L., J, I., D, C., HD, M., DJ, G., & AJ, A. (2026). Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.. Prostate cancer and prostatic diseases. https://doi.org/10.1038/s41391-026-01145-0
Source records
- pubmed · retrieved 2026-09-25T14:41:42.624Z